DEC 1 2 2003

PTO/SB/21 (08-03) Approved for use through 08/30/2003. OMB 0651-0031

Under the Panerwork Reduction Act of 1995	no persoi		nt and Trademark Office; U.S. DEPARTMENT OF COM on of information unless it displays a valid OMB control I		
	TIO DOIDON	Application Number	10/657,533		
TRANSMITTAL		Filing Date	September 8, 2003		
FORM		First Named Inventor	Hector F. DeLuca		
(to be used for all correspondence after initial filing)		Art Unit			
		Examiner Name			
Total Number of Pages in This Submission	6+	Attorney Docket Number	1256-00921		
	ENC	LOSURES (Check all that	t apply)		
Fee Transmittal Form		Drawing(s)	After Allowance communication to Technology Center (TC) Appeal Communication to Board		
Fee Attached		Licensing-related Papers	of Appeals and Interferences Appeal Communication to TC		
Amendment/Reply		Petition Petition to Convert to a	(Appeal Notice, Brief, Reply Brief) Proprietary Information		
After Final		Provisional Application Power of Attorney, Revocation			
Affidavits/declaration(s)		Change of Correspondence Addre	ess Status Letter Other Enclosure(s) (please		
Extension of Time Request		Terminal Disclaimer	Identify below):		
Express Abandonment Request	Request for Refund		Return Receipt Postcard		
Information Disclosure Statement		CD, Number of CD(s)			
Certified Copy of Priority Document(s)	Rema	arks			
Response to Missing Parts/					
Incomplete Application					
Response to Missing Parts under 37 CFR 1.52 or 1.53					
3,33, 3, 3, 1, 1, 1, 1, 2, 1, 1, 1, 2					
SIGNA	TURE (OF APPLICANT, ATTORN	EY, OR AGENT		
Firm Thomas M. Wozr					
or Individual name Andrus, Sceales,					
Signature / Mowas / Woyny					
Date December 9, 200	3				
		CATE OF TRANSMISSION	I/M All INC	=	
		· - · · · · · · · · · · · · · · · · · ·			
			deposited with the United States Postal Service tents, P.O. Box 1450, Alexandria, VA 22313-145		
Typed or printed name Dorothy A. I		er 2			
Signature	A.	(alany	Date December 9,	 2003,	
This call of the state of the same is a second of the OT OF			in a homest but the multipuliable is to Sie (and but the LICE	7704	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.	:	10/657,533)	CERTIFICATE OF MAILING
Applicant	:	Hector F. DeLuca et al)	I hereby certify that this correspondence is
Filed	:	September 8, 2003)	being deposited with the United States
Title	:	2-Methylene-19-Nor-)	Postal Service with sufficient postage as
		$20(S)-25$ -Methyl- 1α -)	first class mail in an envelope addressed to:
		Hydroxycalciferol and)	Commissioner of Patents, P.O. Box 1450,
		Its Uses)	Alexandria, VA 22313-1450, on this 9th
)	day of December, 2003.
TC/A.U.	:)	\sim 1
Examiner	:)	
)	Mothy Muse December 9, 2003
Docket No.	•	1256-00921)	Dorothy A. Hauser Date

INFORMATION DISCLOSURE STATEMENT

Mail Stop: IDS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

The references listed on the enclosed PTO Form 1449 are being submitted in the above-identified patent application in accordance with 37 CFR 1.97(b)(3).

A copy of each of the listed references is enclosed in compliance with the rules.

Respectfully submitted,

ANDRUS, SCEALES, STARKE & SAWALL, LLP

Thomas M. Wozny

Reg. No. 28,922

Andrus, Sceales, Starke & Sawall, LLP 100 East Wisconsin Avenue, Suite 1100 Milwaukee, WI 53202 (414) 271-7590



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/657,533 Filing Date September 8, 2003 INFORMATION DISCLOSURE First Named Inventor Hector F. DeLuca STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number | 1256-00921 Sheet 1 of 4

				DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 5,945,410	08/31/1999	DeLuca et al	
		^{US-} 5,936,133	08/10/1999	DeLuca et al	
		^{US-} 5,877,168	03/02/1999	Miyamoto et al	
	l	^{US-} 5,849,726	12/15/1988	Brenner	
		^{US-} 5,846,960	12/08/1998	Labrie	
		^{US-} 5,843,928	12/01/1998	DeLuca et al	
		^{US-} 5,843,927	12/01/1998	DeLuca	
		^{US-} 5,817,648	10/06/1998	Kutner et al	
		^{US-} 5,587,497	12/24/1996	DeLuca et al	
		^{US-} 5,578,587	11/26/1996	DeLuca et al	
		^{US-} 5,536,713	07/16/1996	DeLuca et al	
		^{US-} 5,246,925	09/21/1993	DeLuca et al	
		^{US-} 5,237,110	08/17/1993	DeLuca et al	
		^{US-} 5,089,641	02/18/1992	DeLuca et al	
	<u> </u>	^{US-} 5,086,191	02/04/1992	DeLuca et al	
		^{US-} 4,666,634	05/19/1987	Miyamoto et al	
		^{US-} 4,800,198	01/24/1989	DeLuca et al	
		US-			
	t	US-			

		FORE	IGN PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T
		0184206	12/1985	Europe		
		0078704	04/1987	Europe		
		0387077	09/1990	Europe		
		0474517	11/1992	Europe		
		0480572	04/1992	Europe		
		0516410	12/1992	Europe		

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND T: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete ii Known			
		Application Number	10/657,533		
18	IFORMATION DISCLOSURE	Filing Date	September 8, 2003		
STATEMENT BY APPLICANT		First Named Inventor	Hector F. DeLuca		
		Art Unit			
	(Use as many sheets as necessary)	Examiner Name			
Sheet	2 of 4	Attorney Docket Number	1256-00921		

		· · · · · · · · · · · · · · · · · · ·	U. S. PATENT D		T =
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
	-	US-	 		
		US-	 		
		US-	 		
		US-			
		US-	+		
		US-			
•		US-	 		
		US-	<u> </u>		
		US-			
		US-	 		
		US-	 		
		US-	 		
	ļ	US-	+		

			IGN PATENT DOCU			
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 "} Number ^{4 "} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ,
•		WO90/09991	09/1990	PCT		
		WO96/01811	01/1996	PCT		匚
						L
						┡
					-	Ļ
	1		i			I .

Examiner	 Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND
T: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons at Substitute for form 1449/PTO	e required to respond to a collection of information unless it contains a valid OMB control number. Compl te if Kn wn			
Cabbalato Iot Iotili 144611 C	Applicati n Numb r	10/657,533		
INFORMATION DISCLOSURE	Filing Date	September 8, 2003		
STATEMENT BY APPLICANT	First Named Inventor	Hector F. DeLuca		
(Use as many sheets as necessary)	Art Unit			
(coo as many snoots as nocessary)	Examiner Name			
Sheet 3 of 4	Attorney Docket Number	1256-00921		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Chemical Abstracts, XP-002066055, Vol. 121, No. 21, November 21, 1994.	
		Posner et al, "2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3-Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing", Journal of Organic Chemistry, 60, pp. 4617-4628, 1995.	
		Slatopolsky et al, "A New Analog of Calcitriol, 19-Nor-1,25-(OH)2 D2 Suppresses Parathyroid Hormone Secretion in Uremic Rats in the Absence of Hypercalcemia", American Journal of Kidney Disorders, 26(5), 832-60, 1995.	
		Posner et al, "Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1Alpha,2Alpha,25-Trihydroxyvitamin D3", Journal of Organic Chemistry, 56, pp. 4339-4341, April 15, 1995.	
		Chemical Abstracts, "Chemistry of Synthetic High Polymers", Vol. 110, No. 10, Abstract 110: 82505v, March 6, 1989.	
		Okano et al, "Regulatory Activities of 2Beta-(3-Hydroxypropoxy)-1Alpha,25-Dihydroxyvitamin D3. A Novel Synthetic Vitamin D3 Derivative on Calcium Metabolism", Biochemical and Biophysical Research Communications, Vol. 163, No. 3, pp. 1444-1449, September 29, 1989.	
		Bouillon et al, "Biological Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D3", Bioactivity of 19-Nor-Pre D, Vol. 8, No. 8, pp. 1009-1015, 1993.	
		Sarandeses et al, "Synthesis of 1Alpha,25-Dihydroxy-19-Norprevitamin D3", tetrahedron Letters, pp. 5445-5448, April 1992.	
		Perlman et al, "1Alpha,25-Dihydroxy-19-Nor-Vitamin D3. A Novel Vitamin D-Related Compound with Potential Therapeutic Activity", Tetrahedron Letters, Vol. 31, No. 13, pp. 1823-1824, February 1990.	
		Baggiolini et al, "Stereochemical Total Synthesis of 1Alpha,25-Dihydroxycholecalciferol and 1Beta,25-Dihydroxyerocalciferol", Journal of Organic Chemistry, 51, pp. 3098-3108, 1986.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Tademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:



PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
p a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known		
Substitute for form 1443/110		Applicati n Number	10/657,533	
INFORMATION DISC	LOSURE	Filing Date	September 8, 2003	
STATEMENT BY AP	PLICANT	First Named Inventor	Hector F. DeLuca	
		Art Unit		
(Use as many sheets as nece	ssary)	Examiner Name		
Sheet 4 of 4		Attorney Docket Number	1256-00921	

	1	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kiegiel et al, "Chemical Conversion of Vitamin D3 to its 1,25-Dihydroxy Metabolite", Tetrahedron Letters, Vol. 31, No. 43, pp. 6057-60660, 1991.	
		Sicinski et al, "New 1Alpha,25-lhydroxy-19-Norvitamin D3 Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogues", Journal of Medical Chemistry, 41, pp. 4662-4674, 1998.	
		Brown et al, "New Active Analogues of Vitamin D with Low Calcemic Activity", Kidney International, Vol. 38, Suppl. 29, 1990, pp. S-22-S-27	
		Hareau et al, "Asymmetric Synthesis of 1Alpha,25-Dihydroxyvitamin D3 A-Ring Precursor Starting with 5-Tert-Butyldimethylsiloxy-2-Cyclohexenone", Tetrahedron Letters, 41, 2000, pp. 2385-2388	

Examiner		Date	
Signature	<u></u>	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{**}EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.